Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

Participants who were given 150,000 endothelial cells experienced an average gain of 11 letters in Best Corrected Visual ...

The trial is structured as a non-randomised, open-label study in patients with relapsed, resistant or metastatic HPV-related ...

Characterised by the overproduction of skin cells, plaque psoriasis leads to itchy or painful inflamed and scaly plaques. Credit: And-One / Shutterstock. Johnson & Johnson (J&J) has reported positive ...

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major kidney outcomes and major ...

The ASI drug class potentially fills an unmet need in the CKD space. Credit: crystal light via Shutterstock. On 15 November ...